Leerink Partnrs Has Positive Estimate for EW Q3 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Investment analysts at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for Edwards Lifesciences in a research note issued on Thursday, May 29th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will earn $0.61 per share for the quarter, up from their previous forecast of $0.60. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2026 earnings at $2.78 EPS.

Several other research analysts have also recently commented on the stock. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a “neutral” rating in a research note on Thursday, April 24th. Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Evercore ISI reduced their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday, February 12th. Finally, Canaccord Genuity Group raised their target price on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a “hold” rating in a research report on Friday, April 25th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $80.20.

Edwards Lifesciences Stock Performance

Shares of NYSE EW opened at $78.09 on Monday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 52-week low of $58.93 and a 52-week high of $95.25. The stock has a market capitalization of $45.81 billion, a price-to-earnings ratio of 11.20, a PEG ratio of 4.82 and a beta of 1.12. The stock’s fifty day simple moving average is $73.35 and its 200 day simple moving average is $72.50.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Edwards Lifesciences’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company earned $0.66 EPS.

Institutional Trading of Edwards Lifesciences

Institutional investors and hedge funds have recently modified their holdings of the company. Crowley Wealth Management Inc. acquired a new position in Edwards Lifesciences during the 4th quarter worth $26,000. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences in the fourth quarter worth about $27,000. Quantbot Technologies LP acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $26,000. SouthState Corp acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth about $27,000. Finally, Rossby Financial LCC bought a new stake in Edwards Lifesciences during the 1st quarter valued at approximately $29,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,500 shares of the stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total transaction of $112,620.00. Following the transaction, the vice president now owns 33,496 shares of the company’s stock, valued at approximately $2,514,879.68. This represents a 4.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Friday, May 9th. The stock was sold at an average price of $74.40, for a total value of $837,000.00. Following the completion of the sale, the chief financial officer now owns 41,098 shares of the company’s stock, valued at approximately $3,057,691.20. This trade represents a 21.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 56,442 shares of company stock worth $4,025,799 over the last ninety days. 0.34% of the stock is currently owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.